BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18347174)

  • 21. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
    Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
    Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.
    Agell L; Hernández S; Nonell L; Lorenzo M; Puigdecanet E; de Muga S; Juanpere N; Bermudo R; Fernández PL; Lorente JA; Serrano S; Lloreta J
    Am J Pathol; 2012 Nov; 181(5):1585-94. PubMed ID: 23083832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes.
    Yaqinuddin A; Abbas F; Naqvi SZ; Bashir MU; Qazi R; Qureshi SA
    Biosci Rep; 2008 Dec; 28(6):319-26. PubMed ID: 18666890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens.
    Li HR; Wang-Rodriguez J; Nair TM; Yeakley JM; Kwon YS; Bibikova M; Zheng C; Zhou L; Zhang K; Downs T; Fu XD; Fan JB
    Cancer Res; 2006 Apr; 66(8):4079-88. PubMed ID: 16618727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
    Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
    Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
    Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
    Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
    Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
    Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implications.
    Sugimura J; Yang XJ; Tretiakova MS; Takahashi M; Kort EJ; Fulton B; Fujioka T; Vogelzang NJ; Teh BT
    Urology; 2004 Aug; 64(2):362-8; discussion 368. PubMed ID: 15302496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
    Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
    Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
    Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
    APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
    Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases.
    Mimori K; Fukagawa T; Kosaka Y; Ishikawa K; Iwatsuki M; Yokobori T; Hirasaki S; Takatsuno Y; Sakashita H; Ishii H; Sasako M; Mori M
    Ann Surg Oncol; 2008 Oct; 15(10):2934-42. PubMed ID: 18661187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
    Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M
    Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of gene expression during nasopharyngeal carcinogenesis revealed by oligonucleotide microarray after microdissection of tumor tissue and normal epithelia from nasopharynx.
    Liu ZQ; Tian YQ; Hu YF; Li XL; Ma FR; Li GY
    Chin Med J (Engl); 2009 Feb; 122(4):437-43. PubMed ID: 19302751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.